These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33004676)

  • 1. Conformational states dynamically populated by a kinase determine its function.
    Xie T; Saleh T; Rossi P; Kalodimos CG
    Science; 2020 Oct; 370(6513):. PubMed ID: 33004676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
    Aleksandrov A; Simonson T
    J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulations provide insights into the origin of gleevec's selectivity toward human tyrosine kinases.
    Wang L; Zheng G; Liu X; Ni D; He X; Cheng J; Lu S
    J Biomol Struct Dyn; 2019 Jul; 37(10):2733-2744. PubMed ID: 30052122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
    ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.
    Verkhivker GM
    Biopolymers; 2007 Mar; 85(4):333-48. PubMed ID: 17167796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of human protein kinase Aurora A linked to drug selectivity.
    Pitsawong W; Buosi V; Otten R; Agafonov RV; Zorba A; Kern N; Kutter S; Kern G; Pádua RA; Meniche X; Kern D
    Elife; 2018 Jun; 7():. PubMed ID: 29901437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
    Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
    J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
    Azam M; Powers JT; Einhorn W; Huang WS; Shakespeare WC; Zhu X; Dalgarno D; Clackson T; Sawyer TK; Daley GQ
    Chem Biol Drug Des; 2010 Feb; 75(2):223-7. PubMed ID: 20028401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases.
    Meng Y; Lin YL; Roux B
    J Phys Chem B; 2015 Jan; 119(4):1443-56. PubMed ID: 25548962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Electrostatic Coupling Enables Conformational Plasticity in a Tyrosine Kinase.
    Tsai CC; Yue Z; Shen J
    J Am Chem Soc; 2019 Sep; 141(38):15092-15101. PubMed ID: 31476863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
    Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity.
    Lin YL; Meng Y; Huang L; Roux B
    J Am Chem Soc; 2014 Oct; 136(42):14753-62. PubMed ID: 25243930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Src-like inactive conformation in the abl tyrosine kinase domain.
    Levinson NM; Kuchment O; Shen K; Young MA; Koldobskiy M; Karplus M; Cole PA; Kuriyan J
    PLoS Biol; 2006 May; 4(5):e144. PubMed ID: 16640460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
    Atwell S; Adams JM; Badger J; Buchanan MD; Feil IK; Froning KJ; Gao X; Hendle J; Keegan K; Leon BC; Müller-Dieckmann HJ; Nienaber VL; Noland BW; Post K; Rajashankar KR; Ramos A; Russell M; Burley SK; Buchanan SG
    J Biol Chem; 2004 Dec; 279(53):55827-32. PubMed ID: 15507431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm.
    Gibbons DL; Pricl S; Kantarjian H; Cortes J; Quintás-Cardama A
    Cancer; 2012 Jan; 118(2):293-9. PubMed ID: 21732333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
    Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
    Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.